Prevalence of anti- beta2GPI antibodies and their isotypes in patients with renal diseases and clinical suspicion of antiphospholipid syndrome

Background: Antiphospholipid antibodies (aPL) are autoantibodies that are associated with a clinical state of hypercoagulability and diverse clinical manifestations collectively known as antiphospholipid syndrome (APS). Objectives: To investigate the prevalence of anti-beta2glycoproteinI-antibodies...

Full description

Saved in:
Bibliographic Details
Main Authors: Sabiha Anis (Author), Ejaz Ahmed (Author), Rana Muzaffar (Author)
Format: Book
Published: Society of Diabetic Nephropathy Prevention, 2013-07-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_ffe4fea3f3d246898f21ed2b3402afb3
042 |a dc 
100 1 0 |a Sabiha Anis  |e author 
700 1 0 |a Ejaz Ahmed  |e author 
700 1 0 |a Rana Muzaffar  |e author 
245 0 0 |a Prevalence of anti- beta2GPI antibodies and their isotypes in patients with renal diseases and clinical suspicion of antiphospholipid syndrome 
260 |b Society of Diabetic Nephropathy Prevention,   |c 2013-07-01T00:00:00Z. 
500 |a 2251-8363 
500 |a 2251-8819 
500 |a 10.12860/JNP.2013.29 
520 |a Background: Antiphospholipid antibodies (aPL) are autoantibodies that are associated with a clinical state of hypercoagulability and diverse clinical manifestations collectively known as antiphospholipid syndrome (APS). Objectives: To investigate the prevalence of anti-beta2glycoproteinI-antibodies (anti-β2GPI) and their isotypes in patients with renal diseases and clinical suspicion of antiphospholipid syndrome (APS). Patients and Methods: This is a retrospective study in which we have analyzed the prevalence of anti-β2GPI and its isotypes in 170 patients on initial testing and in 29 patients repeated after 12 weeks for confirmation of APS. The clinical information was provided by the treating physicians or retrieved from the clinical records. The tests for anti-β2GPI screening and its isotypes (IgG, IgM and IgA) detection were assessed. Results: On initial samples, anti-β2GPI was positive in 118patients. IgA-β2GPI positivity (93; 79%) was significantly higher than IgM and IgG isotypes. Out of anti-β2GPI positive patients, clinical features in 95 patients were suggestive of APS or had SLE. Of these, IgA isotypes was found in 66% (P = 0.010), IgM in 31% (P = 0.033), and IgG in 11% (P = 0.033). On repeat testing, anti-β2GPI was persistently found In 22 patients with a continual predominance of IgA-anti-β2GPI over IgM and IgG isotypes (91% vs. 45.5% and 18% respectively). Conclusions: Our results show that IgA-anti-β2GPI antibodies are the most prevalent isotypes in patients with renal disease or on renal replacement therapy in our population. Thus inclusion of IgA-anti-β2GPI in the testing repertoire may increase the diagnostic sensitivity for APS in patients with renal diseases. 
546 |a EN 
690 |a iga-anti-β2gpi 
690 |a anti-β2-glycoproteini antibodies 
690 |a antiphospholipid syndrome 
690 |a arterio-venous-fistula-formation failures 
690 |a renal aps 
690 |a renal transplant recipients 
690 |a systemic lupus erythematosus 
690 |a Pathology 
690 |a RB1-214 
690 |a Internal medicine 
690 |a RC31-1245 
690 |a Other systems of medicine 
690 |a RZ201-999 
655 7 |a article  |2 local 
786 0 |n Journal of Nephropathology, Vol 2, Iss 3, Pp 181-189 (2013) 
787 0 |n https://nephropathol.com/PDF/jnp-2-181.pdf 
787 0 |n https://doaj.org/toc/2251-8363 
787 0 |n https://doaj.org/toc/2251-8819 
856 4 1 |u https://doaj.org/article/ffe4fea3f3d246898f21ed2b3402afb3  |z Connect to this object online.